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Several large prospective and retrospective studies have demonstrated excellent long-term outcomes after breast conservative
treatment with radiation in invasive breast cancer. Breast-conserving surgery (BCS) followed by radiotherapy (RT) is an accepted
managementstrategyforpatientswithDCIS.Addingradiationtreatmentafterconservativesurgeryenablestoreduce,withoutany
signiﬁcant risks, the rate of local recurrence (LR) by approximately 50% in retrospective and randomized clinical trials. As about
50% of LRs are invasive and have a negative psychological impact, minimizing recurrence is important. Local and local-regional
recurrences after initial breast conservation treatment with radiation can be salvaged with high rates of survival and freedom from
distant metastases.
1.Introduction
The term ductal carcinoma in situ (DCIS) encompasses
a heterogeneous group of lesions with diﬀerent biological
potential and clinical behaviour [1].
There is no consensus regarding how to optimize the
treatment for patients with DCIS: mastectomy cures almost
all patients, but it is considered an overtreatment in many
cases, particularly when they are small mammographic-
detected lesions.
Most women are eligible for breast conservative surgery
(BCS), a major decision is whether or not radiotherapy (RT)
must follow surgical excision in order to control any micro-
scopic residual disease. It is likely that not all patients with
DCIS require RT following BCS; it is important to identify
patients at high risk of recurrence or progression to invasive
breast cancer who can beneﬁt from RT. It is argued that RT
should be used selectively, because of possible short- and
long-termmorbidity,andalsobecauseradiationﬁbrosismay
hamper interpretation of follow-up mammograms.
Unfortunately, until now, the ability to select DCIS that
is likely to recur or progress to invasive breast cancer is still
limited, and there is a lack of level-1 evidence supporting the
omission of adjuvant RT in selected low-risk cases, which
could potentially be adequately treated by complete local
excision.
Patients with DCIS treated with BCS may recur approx-
imately in the same proportion either as DCIS or invasive
breast cancer [2]. Eﬀorts have continued to attempt to
deﬁne the subsets of patients to whom we should oﬀer
the diﬀerent treatment options for local treatment (surgical
excision alone or plus radiation or mastectomy). Most of the
DCIS patients are interested in breast conservative treatment
and consequently a major decision is whether or not to add
radiation treatment. Irrespective of whether a low-risk group
can be identiﬁed, the role of radiation after wide excision of
DCIS remains controversial.
The aim of this paper is to report and summarize the
indications for RT after BCS and the results of retrospective,
prospective randomized studies and meta-analyses on this
issue.
2.RetrospectiveStudies
Published population-based retrospective mono-institu-
tional and collaborative studies have demonstrated excellent
long-term outcomes after BCS with RT.2 International Journal of Surgical Oncology
Multiple observational studies report lower rates of
recurrence(DCISorinvasive)forpatientsundergoingBCS+
RT over BCS alone. All but one [3] of the observational stud-
ies show a lack of mortality beneﬁt associated with BCS + RT
compared with BCS alone.
Surveillance, Epidemiology, and End Results data have
shown that still a substantial number of patients in the
United States are treated with excision alone, without radi-
ation [4].
An international collaborative multi-institutional study
conducted by 10 Institutions in Europe and North America
involving 1003 patients with mammographically detected
DCIS has been published with long-term results [5]. Adju-
vant tamoxifen was not used. The median followup was 8.5
years; the 15-year overall survival (OS) was 89%, and the 15-
year cause-speciﬁc survival (CSS) was 98%.
T h er a t eo fa n yl o c a lr e c u r r e n c e( L R )( D C I Sp l u s
invasive) was 19%. Signiﬁcant factors for LR were found to
be the ﬁnal pathologically positive margins and the patient’s
youngerage.Forthefavorablesubgroupofpatientsaged ≥50
years with negative margins, the 10-year rate of local failure
was ≤8%.
A retrospective French collaborative study reported on
882 DCIS treated from 1985 to 1995 [6]. Mastectomy, BCS
alone, and BCS + RT were performed, respectively, in 20%,
22%, and 58% of patients. Thus 515 women out of 705,
who were treated with BCS, received adjuvant RT; a 10Gy
boost was given to 52% of them. Hormonal therapy was
administered to 13.4% of the patients. The crude 7-year LR
rate was 2% (mastectomy subgroup), 31% (BCS subgroup),
and 13% (BCS + RT subgroup) (P<0.0001). RT reduced
the LR rate by 65% in all histological subgroups, especially
in comedocarcinoma and mixed cribriform/papillary sub-
groups.
The most numerous single institution series was pub-
lished by the William Beaumont Hospital (USA) in 2005
[7]. Between 1981 and 1999, 410 cases were treated; 367
were managed with BCS (54 with lumpectomy alone and
313 with adjuvant RT—median dose: 45Gy). Of these 313
patients, 298 received also a boost with a median dose
of 16Gy. Thirty patients (8.2%) experienced an ipsilateral
breast tumor recurrence after breast conservative treatment;
25/313 patients (8%) after RT, 5/54 (9.3%) after BCS alone,
and 2/43 (4.7%) developed a chest wall recurrence after
mastectomy. Ten-year rates of LR, CSS, and OS were similar
after mastectomy and breast conservative treatment. Young
age(<45years),close/positivemargins,nobreastirradiation,
and lower electron boost energies (≤9MeV) were associated
with a higher risk of LR.
Schouten van der Velden et al. [8] published the results
of a multicenter dutch retrospective study on 798 women
treated between 1989 and 2003, selected by the Tumor
Registry of the Comprehensive Cancer Centre East Nether-
land. The 5-year recurrence-free survival (RFS) was 75%
for BCS alone (237 patients) compared to 91% for BCS
followed by RT (153 patients) and 99% for mastectomy
(408 patients) (P<0.01). Independent risk factors for
LR were treatment strategy, symptomatically detected DCIS,
and presence of comedo necrosis. Margin status reached
statistical signiﬁcance only for patients treated with BCS.
Av e r yl a r g er e t r o s p e c t i v ee x p e r i e n c ei sr e p o r t e db yt h e
Van Nuys group [9]. Nine hundred and nine cases were
reported, treated from 1971 to 2000; 326 of them underwent
mastectomy, 237 BCS + RT, and 346 BCS alone. In the
group of patients treated conservatively (583), the LR rate
was 28% after BCS alone and 20% after BCS + RT (P =
0.06), with a median time to LR of 25 and 57 months,
respectively (P<0.01). It has to be noted that in the
RT group there were more patients with “close” (<1mm)
margins (35% versus 19%), and the median followup was
36 months longer. After having observed the importance
of several factors (grading and comedo necrosis, size, and
margins), Silverstein et al. proposed the well-known Van
Nuys Prognostic Index (VNPI) [10] based on a three-point
score for each predictor. In 2003, they added age to their
prognostic score [11], identifying three risk subgroups: ≤39
years of age (high score), 40–60 years of age (intermediate
score), and ≥61 years of age (low score). To patients with
a low score (from 4 to 6), conservative surgery alone was
recommended, to those with an intermediate score (from 7
to 9) postsurgical RT, and to those with a high score (from 10
to12)mastectomy,sincetheLRincidenceat5yearsappeared
too high (around 50%) with a BCS + RT treatment.
Although a simple, and apparently easy task, this score,
based on retrospective analysis of Van Nuys case studies, has
not been easily reproduced in clinical practice and has not
been still validated in a prospective study [12, 13].
Another collaborative group in Italy published the data
of 139 cases of DCIS treated with BCS + RT, with a median
followupof81months[14].ActuarialOS,CSS,andRFSat10
years were 93%, 100%, and 86%. The same group reported
on 112 cases of subclinical DCIS treated between 1982 and
1993 [15]. At a median followup of 66 months, 8 LRs were
observed, with a 10-year actuarial CSS and RFS of 100% and
91%, respectively.
In a recent retrospective study of the same group, in
which 586 patients treated with BCS + RT were analyzed, the
risk of LR was found to be 9.6% at 10 years. The risk of LR
with respect to a number of known prognostic parameters
(age, tumour size, nuclear grade) was evaluated. Only age
resulted to be a statistically signiﬁcant prognostic factor in
the univariate analysis (P = 0.0009). The actuarial 10-
year OS and CSS were 98.5% and 99%, respectively (data
submitted for publication).
2.1. Meta-Analysis of Retrospective Studies. In 1999, Boyages
et al. [2] published a meta-analysis of the most important
retrospective studies for DCIS, that had undergone diﬀerent
treatments: mastectomy (1574 cases), BCS alone (1148
cases), and BCS + RT (1452 cases). The meta-analysis
revealed that the relapse incidence was of 22.5% after BCS
alone (with 43% invasive LR), 8.9% after BCS + RT (with
50% invasive LR), and of 1.4% after mastectomy (with 76%
invasive LR). Considering only the conservative treatment,
theRTreducedtherelativeLRriskofatleast50%.Themajor
advantage on local control was noted in cases of DCIS withInternational Journal of Surgical Oncology 3
necrosis,comedocarcinoma,highnucleargrade,andpositive
or “close” margins.
3.RandomizedClinicalTrials
The impact of RT after conservative surgery in women with
newly diagnosed DCIS has been analyzed in four prospec-
tive randomized clinical studies. The patients had under-
gone conservative surgery consistent of quadrantectomy,
tumorectomy, or segmental mastectomy.
Inthreeofthesestudies,acomparisonwasmadebetween
the results of BCS alone and BCS followed by breast
irradiation (two arms of randomization). A 2 × 2f a c t o r i a l
design was used in the fourth study; the aim was to see
the eﬀectiveness of either adjuvant RT or hormonal therapy
with Tamoxifen (TAM); allocation of patients could have
happened for both treatments (RT and TAM) or just for one
of the two, reserving the second as the only other choice.
The ﬁrst study, the American NSABP-B-17 trial [16],
randomized 818 cases of DCIS, between October 1985
and December 1990, 80.4% of which mammographically
diagnosed (Table 1).
T h ep r o t o c o lr e q u i r e dh i s t o l o g i c a ln e g a t i v em a r g i n s ;
however, inking of excision margins and specimen radiog-
raphy were not routinely used in that era. Thus, in a central
pathology review on histopathologic specimen, uncertain or
positive margins were found in 17% of the cases [17].
The cumulative incidence of ipsilateral events, with a
median followup of 12 years, was of 31.7% for the control
group, compared to 15.7% for the group with RT (P<
0.000005); 76% were true LR within the same quadrant.
Considering the invasive LR, the incidence lowered from
16.8% (control group) to 7.7% (RT group) (P = 0.00001);
while for DCIS LR, it lowered from 14.6% to 8.0% (P =
0.001). Neither the cumulative incidence of contralateral
tumors nor the OS (P = 0.80) diﬀered signiﬁcantly between
the two groups.
Recently, the long-term results of the NSABP B-17 and
B-24 trials have been published [18]. In the NSABP B-17
study, with a median followup of 207 months, the signiﬁcant
contribution of RT in reducing the ipsilateral events is
conﬁrmed (Table 2).
The regional recurrence and the distant metastasis inci-
dence are comparable in the two groups; also the con-
tralateral tumor incidence results are very similar as well as
mortality from breast carcinoma or other causes.
The evaluation of the predictive factors was referred to
in a publication from 1999 [17], in which were analyzed the
results of a centralized pathological revision of 623 trial cases
(77%ofallstudycases).Withamedianfollowupof8.5years,
in the multivariate analysis only comedo necrosis was found
to be an independent predictive variable for LR. However, it
wasobservedthatwithinallprognosticsubgroups,anoverall
beneﬁt from the use of RT was maintained.
In the second study, the European EORTC-10853 [19],
1010 patients, treated between March 1986 and July 1996,
were randomized; in 71% of the cases the initial diagnosis
was exclusively mammographic (Table 1).
The arm with RT received a total dose of 50Gy in 25
fractions; only 5% of the patients received an additional
boost with a median dose of 10Gy. Negative margins rep-
resented one of the inclusion criteria; however, a centralized
pathologic revision of 863 of the 1010 randomized cases
(85%) revealed that the margins were positive or “close”
(≤1mm) for 8.5% of the cases, and not known in 13.5%
cases [20].
The LR rate, with a median followup of 10.5 years, was
of 26% in the control arm, compared to 15% in the RT arm
(P<0.0001). In the RT group was noted a decrease in the
risk of invasive LR and DCIS LR of 42% (P = 0.0065) and
of 48% (P = 0.0011), respectively (Table 2). The incidence of
contralateral breast tumors, of regional and distant relapse,
and OS demonstrated no signiﬁcant diﬀerence within the
two groups.
In the multivariate analysis of the prognostic factors,
young age (≤40 years), symptomatically detected DCIS, high
nuclear grade (G2-3), solid/comedo or cribriform growth
pattern, and the absence of free margins were associated
with an increased risk of LR. Similarly to the ﬁndings of the
NSABPB-17trial,RTreducedtheriskofLRinallprognostic
subgroups considered.
The third study, the Swedish SweDCIS [21], was con-
ducted between September 1987 and December 1999; 1046
patients out of 1067 randomized women were eligible to
the statistical evaluation, with a mean followup of 8.4 years.
In 823/1046 cases (78.7%), the DCIS was discovered in a
mammographic screening (Table 1).
In the RT arm, treatment could be given either contin-
uously (total dose: 50Gy, 25 fractions) or in a split-course
schedule (54Gy given in two series with a gap of two weeks),
which was administered in less than 50 cases; no RT boost
was given to the tumor bed. The protocol did not require
pathologically negative margins, thus in 11% of the cases,
the margins were positive and in 9% they were unknown.
The diﬀerence of the LR rate was signiﬁcant: 27.1% in the
control group compared to 12.1% in the other one. The
invasive LR were reduced from 12.3% to 7.2% and the DCIS
LR from 14.8% to 4.9% with RT (Table 2). The incidence
of contralateral events, metastasis, and death due to breast
carcinoma did not present signiﬁcant diﬀerences within the
two groups.
Considering the main prognostic factors, a correlation
betweenRTeﬀectivenessandagewasnoted(P = 0.07),more
evident for women over 60 years (risk reduction of 18%)
[20].
In a previous study [22] that had investigated the histo-
pathologic risk factors for LR by a slide revision of 2 cohort
cases from the trial, high nuclear grade and necrosis were
associated to a major local relapse risk. RT has conferred a
reduction of relapse risk in all prognostic subgroups.
The fourth study, the English, Australian and New
Zealand UK/ANZ DCIS trial [23], was conducted from May
1990 in Great Britain and September 1991 in Australia
and New Zealand to August 1998 (Table 1). The protocol
required the complete excision of the lesion, the radiography
of the surgical specimen, and the presence of free micro-
scopic margins. In the two arms with RT (RT, RT + TAM),4 International Journal of Surgical Oncology
Table 1: Characteristics of the prospective randomized trials.
NSABP-B17 EORTC 10853 SweDCIS UK/ANZ DCIS
Entry dates 1985–1990 1986–1996 1987–1999 1990–1998
Pts. randomized 818 1010 1067 1030
CS 405 503 533 508
CS + RT 413 510 534 522
Mammographic detection 80.4% 71% 78.7% NS
Central pathological review 76% 85% 26% 0%
Negative margins required Yes Yes No Yes
Margins free 78% 83% 80% 100%
RT dose 50Gy/25fr. 50Gy/25fr. 50–54Gy/25–27fr. 50Gy/25fr.
B o o s t 1 0G y / 5f r .( 9 %o fp t s . ) 1 0G y / 5f r .( 5 %o fp t s . ) N R N R
Legend: Pts: patients; NS: not speciﬁed; NR: not recommended; RT: radiotherapy; CS: conservative surgery; fr.: fractions.
Table 2: Comparison of breast cancer events in prospective randomized trials.
NSABP-B17
(17.25yrs. median FU)
EORTC 10853
(10.5yrs. median FU)
SweDCIS
(8.4yrs. mean FU)
UK/ANZ DCIS
(12.7yrs. median FU)
CS % CS + RT% CS% CS + RT% CS% CS + RT% CS% CS + RT%
Ipsilateral events
Total 35.0 19.8 26.0 15.0 27.1 12.1 19.4 7.1
Invasive 19.6 10.7 13.0 8.0 12.3 7.2 9.1 3.3
In situ 15.4 9.0 14.0 7.0 14.8 4.9 9.7 3.8
Contralateral events 7.9 9.3 4.0 8.0 5.9 6.5 4.1 3.3
OS% 86∗ 87∗ 95 95 90∗∗ 92∗∗ 97.9# 96.2#
∗At 12yrs. followup.
∗∗Breast cancer deaths and other deaths are reported in the study.
#All trial participants included.
Legend: yrs.: years; FU: followup; OS: overall survival; RT: radiotherapy; CS: conservative surgery.
the total dose was of 50Gy in 25 fractions, without boost on
the tumor bed; in the two hormonal-therapy arms (TAM,
TAM + RT), the TAM dose was of 20mg/die for 5 years.
The recent update of the study [24]h a sam e d i a n
followup of 12.7 years, and it contains 1694 patients, 1030
of which were assigned to randomization for RT. In such a
group, the incidence of ipsilateral events was of 19.4% in the
control arm and of 7.1% in the RT arm (P<0.0001), with,
respectively, 9.1% and 3.3% of invasive carcinomas and 9.7%
and 3.8% of noninvasive ones; the incidence of contralateral
tumors was of 4.1% in the control arm and of 3.3% in the
RT arm (P = 0.6) (Table 2). Overall, there was no signiﬁcant
diﬀerence in the death rate within the diﬀerent subgroups.
It was noted an increase in cardiovascular deaths within
the patients treated with RT, with or without TAM (P =
0.008), although the numbers were small. Death due to
breast carcinoma proved to be higher within the patients
that received hormonal treatment, but the diﬀerence was not
signiﬁcant [24].
3.1. The Meta-Analyses of Randomized Trials. The ﬁrst meta-
analysis of the four randomized trials was published by Viani
et al. in 2007 [25].
The overall statistical evaluation of 3665 patients pointed
out a reduction in LR risk (either invasive or DCIS) of
approximately 60% with the addition of adjuvant RT,
compared to excision alone. Such reduction in risk was
more evident in the cases with high nuclear grade and
positive margins, even though it was not possible to identify
a subgroup of women with low LR risk who did not need
to be treated with RT. Within the two groups, no diﬀerences
appeared between the incidence of distant metastasis and the
OS rate. The probability of contralateral breast carcinoma
proved to be 1.53 times higher in the RT arm (3.85% versus
2.5%, P = 0.03). In the subsequent meta-analyses, which
haveexaminedthedataofthefourtrialsafteralongerfollow-
up period, such diﬀerence was minimal and did not prove to
be statistically signiﬁcant.
In 2009, Goodwin et al. [26] published a systematic
review and a meta-analysis of the four trials; a more detailed
version was published in the Cochrane Library [27].
From the statistical analysis, conducted on 3925 women,
a signiﬁcant reduction of ipsilateral events with adjuvant
RT resulted (HR = 0.49; 95% CI 0.41–0.58, P<0.00001).
The authors investigated the role of breast irradiation in
relation to some prognostic parameters: margin status, ageInternational Journal of Surgical Oncology 5
(>50 versus <50 years), and presence of comedo necrosis; in
all the analyzed prognostic subgroups the contribution of RT
was signiﬁcant.
In very few cases, severe cardiovascular toxicity or the
appearance of a second primary tumor was observed, but
with very similar numbers within the two groups. The
median followup of the trials included in the meta-analysis
varied from 4.4 to 10.5 years; the authors hypothesized that
with a longer followup, an increase of RT late toxicity could
appear [26].
In 2010, the meta-analysis of the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) was published
[28]. The statistical analysis showed that RT is able to reduce
the absolute risk of ipsilateral events of 15.2% at 10 years
(12.9% versus 28.1%, logrank 2P<0.00001) and that its
eﬀectiveness does not diﬀer signiﬁcantly in relation to age,
extension of the surgical procedure, association with TAM,
diagnostic method, status of the margins, focality, nuclear
grade, presence of comedo necrosis, architectonic pattern,
and dimension of the tumor. Regarding age, a reduction of
the ipsilateral events was noted in women ≥50 years of age.
The authors examined a subgroup of 291 cases out of the
meta-analysis with low risk (tumor dimension ≤20mm,
negative margins and grade 1); even in such a very favourable
subgroup they conﬁrmed a signiﬁcant reduction in the 10-
year risk of ipsilateral events of 18.0% with RT (logrank
2P = 0.002).
4. Prognostic Factors
Actually, there is no evidence from observational studies and
clinical trials that BCS plus RT is more or less eﬀective than
BCS without RT in the presence or absence of particular
adverse prognostic factors, with RT being more eﬀective in
all subsets of patients.
BCS alone, even though not detrimental in terms of
survival, is a treatment at high risk of LR.
Eastern Cooperative Oncology Group (ECOG) reported
a registration study (ECOG E5194) aimed to prospectively
identify favorable patients with DCIS treatable with local
excision alone [29]. With a median followup of 6.2 years, the
7-year rate of LR was 10.5% for the 565 patients with low-
or intermediate-grade DCIS; with a median followup of 6.7
years, the 7-year rate of LR was 18.0% for the 105 patients
with high-grade DCIS. On multivariate analysis, no variable
was signiﬁcantly associated with LR.
Another study has demonstrated similar ﬁndings for a
cohort of patients treated with BCS alone [30].
Wong et al. [36] reported on 158 patients treated with
wide excision alone, with a minimum negative margin width
of 1.0cm. The 5-year rate of LR was 12%; the study,
therefore, was closed early because of the negative results.
4.1. Clinical Factors. The major clinical factors associated
with an increased risk of LR following breast-conserving
treatmentforDCISaresymptomaticpresentationandyoung
patient age at diagnosis [37].
4.2. Pathologic Factors. The most frequently reported factors
associated with a higher risk of LR are high nuclear grade,
comedo necrosis, and larger tumor size.
In the NSABP-B17 trial, the presence of comedo necrosis
was associated with a higher risk of LR, limited, however, to
the group of patients treated with excision alone [18]. In that
group, LR rate at 8 years was 40% for cases with moderate
or marked comedo necrosis compared to 23% for patients
without it.
Data published by Silverstein et al. [10] showed that
marginwidthsof10mmormorehaveariskofLRunaﬀected
bynucleargradeandadditionofRT.Incontrast,thesefactors
remained signiﬁcant in the group of patients with small
margin widths [38].
The impact of DCIS grade on LR risk appears to be
related to the length of followup, as emphasized in the study
of Solin et al. [5]. In this study, comedo architecture and
nuclear grade 3 had a signiﬁcantly higher 5-year LR rate; the
diﬀerence, however, was no longer statistically signiﬁcant at
10 years.
These data suggest that risk factors for noninvasive
and invasive LR may not be identical, that the analysis of
the combination of these events into a single group may
obscure important diﬀerences and that the biological basis
for noninvasive and invasive LR may be diﬀerent.
4.3. Margins. Multiple retrospective studies and some clin-
ical prospective trials have shown that achieving patho-
logically conﬁrmed negative margins is associated with a
decreased rate of LR. The evaluation of the involvement of
themarginsofexcisionisoneofthefewclinicalvariablesthat
can be controlled even though the deﬁnition of a negative
margin varies from study to study (1, 2, 5, or even 10mm).
Dunne et al. [39] reported a meta-analysis of 4660
patients treated with BCS + RT from 22 studies with data
on margins of resection. The odds ratio for LR was 2.56
(P<0.05), 2.89 (P<0.05), and 1.51 (P>0.05) for a
minimum negative margin width of no tumor cells, 1mm
and 2mm on ink, respectively.
A minimum negative margin width of 2mm was consid-
ered appropriate in the setting of adding RT after lumpec-
tomy. On the contrary, a minimum negative margin width
of 10mm has been recommended when using lumpectomy
alone [38].
In some series, a small number of patients with close or
positive margins is reported. In these cases with focally close
or positive margin of resection, reexcision is the preferred
next step. If a reexcision cannot be performed, deﬁnitive
irradiationcanbedeliveredwithaslightlyhigherriskoflocal
failure. The excess risk of LR in this setting is estimated of
approximately 5%–7% [39, 40].
5. SalvageTreatment for Local Recurrence
SinceDCISisassociatedwithalowrateofmortality,analyses
of the success of treatment should focus on recurrence.
One of the arguments advanced in favor of omitting
radiation after BCS at the time of initial presentation is the
hypothetical ability to repeat a salvage breast conservative6 International Journal of Surgical Oncology
treatment. However, few data have been reported on this
argument. Salvage mastectomy is frequently indicated fol-
lowing LR, particularly when reexcision would be cosmeti-
cally unacceptable, or when an adjuvant RT was previously
performed.
The rate of salvage breast conservation is only 42%–52%
after primary BCS and some patients can reject secondary
breastconservationinfavorofmastectomy.Thus,preventing
LR by adding RT at the time of initial treatment may be a
more important long-term strategy.
A dedicated study [41] reported 90 patients with local or
local-regional recurrence as the site of ﬁrst failure. Salvage
surgery was mastectomy for 76/90 (84%) patients. The
median followup was 5.5 years after salvage treatment; 10-
year OS and CSS were 83% and 95%, respectively; 10-year
rate of freedom from distant metastases was 91%.
Localandlocal-regionalrecurrencescanbesalvagedwith
high rates of survival and freedom from distant metastases.
Careful followup is warranted for the early detection of
potentially salvageable recurrences.
6.ParticularAspects of DCISIrradiation
6.1.RoleoftheBoost. Theadvantageofanadditionalboostto
the tumor bed after BCS and whole breast irradiation (WBI)
for invasive breast cancer has been conﬁrmed by controlled
clinical trials [42, 43] and is now a standard of care. Whether
this is applicable to patients with pure ductal carcinoma in
situ (DCIS) is unclear.
The importance of a boost in the local control of DCIS
has been examined in 6 retrospective studies [31–35, 44]
(Table 3), while no prospective randomized study has been
published so far on this issue.
In two trials, the role of the addition of a boost is studied:
the BIG 3-07/TROG 07.01 and the BONBIS multicenter
study [45, 46]. In both trials the accrual of the patients is still
ongoing.
Of particular interest are the results of the international
multicenter retrospective study by Omlin et al. [31]: 373
patients ≤45 years old were treated with BCS only (15%),
BCS followed by WBI (45%), or BCS and WBI followed by
a boost on the tumor bed (40%). The authors observed a
progressive increase of local relapse-free survival at 10 years,
starting from BCS without WBI (46%), to WBI without
boost (72%), to WBI followed by boost (86%) (P<0.0001).
In the multivariate analysis, margin state and RT dose
resulted as independent predictive factors of local relapse-
free survival; the major advantage correlated to the delivery
of the boost was noticed in young women (≤39 years).
Considering thelimits of this study (retrospectivedesign,
with a very long accrual period of 26 years and lacking a
centralized revision of tumor-sample histology), and while
waiting for the results of the randomized clinical trials in
course, it would be appropriate to consider a boost after WBI
for women aged 45–50 or younger.
6.2. Hypofractionated RT. Recently, a considerable interest
for hypofractionated RT schedules was noted, either in the
form of whole- or partial-breast treatment.
The considerable duration of the whole treatment with
conventional RT (from 5 to 6.5 weeks), associated with the
distance fromthepatients hometothe Radiotherapy Centers
andthelongwaitinglists,representsmatter-of-factcriticality
factors of standard breast RT.
6.2.1. Hypofractionated WBI. The eﬃcacy of hypofraction-
ated WBI, in the treatment of invasive breast cancer after
conservative surgery, has been conﬁrmed by retrospective
studies and by some recent randomized trials, which account
excellent results both in terms of local-regional control and
cosmetic outcome [47].
As long as DCIS is concerned, so far only two prospective
phase I and II studies have been published [48, 49].
The study of Constantine et al. [49] is the only one
that included exclusively patients with mammographically
detected pure DCIS (59 cases) treated with hypofractionated
WBI, for a total dose of 42Gy in 15 fractions. With a still
limitedfollowup(36months)noLRsorcontralateraltumors
were found.
The study of Freedman et al. [48] examined together
women with early invasive carcinoma and with DCIS. The
patients underwent a treatment of the whole breast with
IMRT, at a total dose of 45Gy in 20 fractions and a
concomitant boost on the tumor bed to a total dose of 56Gy
(2.8Gy/fr.in20fractions).To-date,onlydatarelativetoacute
toxicity and cosmetic results have been published.
Also some retrospective studies [35, 44, 50, 51] show
optimal results in terms of local control in DCIS with
hypofractionated treatment.
No phase III prospective study has been published until
now; in 2007, the above-mentioned international multi-
center BIG 3-07/TROG 07.01 trial was initiated, and it
confronted both the conventional RT schedule versus the
hypofractionatedone,andtheboostversusno-boostdelivery
[45, 46]. The patients’ accrual has not been closed so far:
some years are needed before the results can be published.
6.2.2. Partial Breast Irradiation (PBI). PBI has been widely
proposed as the treatment for early-stage invasive breast
cancer; options include brachytherapy techniques (using
either the interstitial catheters or the intracavitary device
MammoSite), external-beam RT (3D-CRT or IMRT), and
intraoperative radiotherapy.
It seems more controversialwhenit is usedto treat DCIS,
based on the knowledge of the growth pattern of this tumor
within the complex ductal-lobular system of the breast [52].
According to a recent Consensus Statement of the
ASTRO (American Society for Radiation Oncology) [53],
which has established the criteria for the inclusion of PBI,
outside the clinical trials, the partial irradiation for pure
DCIS is to be evaluated with caution if the tumor diameter
is ≤3cm and is not indicated if the diameter is >3cm.
T h e r e f o r e ,f e ws t u d i e sh a v ed o c u m e n t e dt h ee ﬃcacy of PBI
in treating DCIS so far [54].
The American Society of Breast Surgeons (ASBS) has
recently published an update on the DCIS case studies
included in the MammoSite Registry Trial, that represents
the widest prospective database published until now [55].International Journal of Surgical Oncology 7
Table 3: The inﬂuence of the boost on local control.
Studies N. of pts. Median age (y) Positive margins % Necrosis % Median FU (months) LR %
Omlin et al. [31]
Boost 150 41∗ 73 2 7 21 4 ∗∗
No boost 166 4 41 28∗∗
Yerushalmi et al. [32]
Boost 20 58 / / 81 15
No boost 55 / / / 12.7
Julian et al. [33]
Boost 692 53 21 52 168 13.8
No boost 877 15 45 14.3
Monteau et al. [34]
Boost 147 53 50 60 89 9.3∧
No boost 55 74 64 9.6∧
Wai et al. [35]
Boost 144 56 29 46 112 9∗
No boost 338 55 12 55 6∗
Wong et al. [44]
Boost 79 58 5 56 46 0
No boost 121 0.8 49 6
∗All < 45 years, ∗∗10-year LR, ∧7-year LR, #Reexcision for close (<2mm) margins.
Legend: pts.: patients; (y): years; FU: follow up; LR: local recurrence.
For194patients,withamedianfollowupof54.4months,the
5-year actuarial LR rate is of 3.39% and the cosmetic results
are favorable in 92% of the cases.
In2005,aphaseIIIprospective,randomized,multicenter
study, NSABP B-39/RTOG 0413, was started [45, 54]. It
compared WBI to PBI. Patients with DCIS or with stage I
or II invasive carcinoma (T ≤ 3cm),N− or N+ (≤3 N+),
are being treated with lumpectomy and then randomized
to either WBI (±boost) or PBI with one of the 3 following
techniques: interstitial multicatheter brachytherapy (34Gy–
3.4Gy/fr, BID), brachytherapy with MammoSite (34Gy–
3.4Gy/fr, BID), 3D-CRT (38.5Gy–3.85Gy/fr, BID).
The results of this trial will be very important in
ﬁnding out the long-term eﬃcacy of PBI, both for invasive
carcinoma and DCIS.
It should be noted that PBI does not represent a
therapeutic standard, neither for invasive carcinoma, nor
for DCIS; the randomized studies in progress will have to
evaluate the relapse risk, the cosmetic results, and long-term
toxicity.
7. Conclusions
Randomized trials provide consistent evidence that DCIS
treated with breast-conserving surgery plus radiation com-
pared to BCS alone results in a reduction of noninvasive LR
and of invasive LR by approximately 50%. As breast cancer
speciﬁc survival after DCIS is uniformly excellent, the major
measure of treatment eﬀectiveness has generally been the LR
rate.
Subset analyses of randomized controlled trials do not
point out to diﬀerential eﬀectiveness of surgery versus RT in
the presence of some adverse prognostic factors. This sug-
gests that treatment alone may not eliminate the adverse
prognosis. However, it also suggests that for patients with
adverse prognostic features, treatment may be particularly
important.
Studiesofnewirradiationmodalities(PBI,hypofraction-
ation) in DCIS patients are currently ongoing and deserve
further attention.
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